182 related articles for article (PubMed ID: 3878574)
1. Serum levels of prostatic acid phosphatase (PAP), tissue polypeptide antigen (TPA), CA-50, neopterine and of osteocalcin in patients with prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Eriksson A; Nordström L
Scand J Clin Lab Invest Suppl; 1985; 179():75-80. PubMed ID: 3878574
[No Abstract] [Full Text] [Related]
2. On reference values for tumor markers in prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Kallner A
Scand J Urol Nephrol Suppl; 1988; 110():119-23. PubMed ID: 3263693
[TBL] [Abstract][Full Text] [Related]
3. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer.
Kuriyama M; Loor R; Wang MC; Lee C; Killian CS; Papsidero LD; Inaji H; Nishiura T; Slack NH; Murphy GP; Chu TM
Int Adv Surg Oncol; 1982; 5():29-49. PubMed ID: 6178696
[No Abstract] [Full Text] [Related]
4. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
[TBL] [Abstract][Full Text] [Related]
5. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.
Huber PR; Rist M; Hering F; Biedermann C; Rutishauser G
Urol Res; 1983; 11(5):223-6. PubMed ID: 6659214
[TBL] [Abstract][Full Text] [Related]
7. Aspects on reference values for tumor markers in human prostatic carcinoma.
Ekman P; Lewenhaupt A; Eneroth P; Kallner A
Am J Clin Oncol; 1988; 11 Suppl 2():S80-2. PubMed ID: 2468281
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma.
Larson A; Fritjofsson A; Norlén BJ; Gronowitz JS; Ronquist G
Scand J Clin Lab Invest Suppl; 1985; 179():81-8. PubMed ID: 2417306
[No Abstract] [Full Text] [Related]
9. Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
Marczyńska A; Kulpa J; Leńko J; Augustyn M
Int Urol Nephrol; 1988; 20(2):123-9. PubMed ID: 2454895
[TBL] [Abstract][Full Text] [Related]
10. Immunologic markers and the diagnosis of prostatic cancer.
Ban Y; Wang MC; Chu TM
Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
[TBL] [Abstract][Full Text] [Related]
11. [What is the use of the radioimmunoassay of prostatic acid phosphatase?].
Luckacs B; Cohen L; Coloby P; Gattegno B; Michel F; Agnes E; Roland J; Thibault P
J Urol (Paris); 1985; 91(4):211-4. PubMed ID: 2410516
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
Morote Robles J; de Torres Mateos JA; Soler-Roselló A
Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015
[No Abstract] [Full Text] [Related]
13. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
[TBL] [Abstract][Full Text] [Related]
14. [Tissue polypeptide antigen as a marker for prostatic neoplasms. Preliminary study].
Ruibal A; Durán P; Ibarz L; Fraile M; Roca I; de Torres Mateos JA
Arch Esp Urol; 1984; 37(5):399-403. PubMed ID: 6517625
[No Abstract] [Full Text] [Related]
15. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
16. [New prospective diagnostic serum markers in prostatic cancer].
Mirone V; De Bellis G; Prezioso D; Sanseverino R; Iannucci F; Padulano P
Minerva Med; 1986 Mar; 77(13):503-4. PubMed ID: 2422605
[No Abstract] [Full Text] [Related]
17. [Tumor marker in urology].
Shimazaki J; Ito H; Miyauchi T; Maruoka M; Isaka S; Masukagami T; Ando K
Gan No Rinsho; 1983 May; 29(6):684-92. PubMed ID: 6192269
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactive prostate-specific acid phosphatase in prostatic cancer.
Kontturi M; Vihko P; Lukkarinen O; Vihko R
Scand J Clin Lab Invest Suppl; 1985; 179():67-74. PubMed ID: 3866311
[No Abstract] [Full Text] [Related]
20. [Purification and determination of human prostate specific antigen in the serum].
Ogawa Y; Morikawa J; Ohsawa R; Machida T; Miki M; Yanagisawa M
Radioisotopes; 1984 May; 33(5):273-8. PubMed ID: 6206524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
